After a years-long feud, Vertex reached a deal with the U.K.
In what looks like the end of a lengthy dispute, Vertex Pharmaceuticals has found a compromise with regulators in the U.K. over the cost-effectiveness of its treatments for cystic fibrosis.
As STAT’s Ed Silverman reports, the four-year agreement guarantees reimbursement for Vertex’s latest medicine, soon to be approved for about 90% of cystic fibrosis patients. In exchange, the company will submit additional evidence on three of its treatments to the nation’s cost-effectiveness agency. Neither party disclosed pricing details.
The agreement ends a standoff that frustrated patients and advocacy groups, as Vertex’s protracted disagreement with U.K. authorities left many unable to access medicines with well-established benefits. It also signals a way forward for other drug makers locked in disputes with European governments.
Read more.
As STAT’s Ed Silverman reports, the four-year agreement guarantees reimbursement for Vertex’s latest medicine, soon to be approved for about 90% of cystic fibrosis patients. In exchange, the company will submit additional evidence on three of its treatments to the nation’s cost-effectiveness agency. Neither party disclosed pricing details.
The agreement ends a standoff that frustrated patients and advocacy groups, as Vertex’s protracted disagreement with U.K. authorities left many unable to access medicines with well-established benefits. It also signals a way forward for other drug makers locked in disputes with European governments.
Read more.
No hay comentarios:
Publicar un comentario